SkinHealth Systems financials
$0.6211−4.45%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $300.8M | $334.3M | $398.0M | $365.9M | $260.1M |
| Gross profit | $196.4M | $182.3M | $155.1M | $248.8M | $178.5M |
| Gross margin | 65.3% | 54.5% | 39.0% | 68.0% | 68.6% |
| Operating income | -$20.8M | -$67.8M | -$130.9M | -$25.8M | -$39.9M |
| Net income | -$9.5M | -$29.1M | -$100.1M | $44.2M | -$378.8M |
| Net margin | −3.2% | −8.7% | −25.2% | 12.1% | −145.6% |
| Diluted EPS | $-0.16 | $-0.36 | $-0.76 | $-0.23 | $-3.71 |
| EBITDA | $4.5M | -$34.1M | -$96.2M | -$3.0M | -$22.0M |
| Operating cash flow | $37.5M | $16.1M | $21.8M | -$106.6M | -$28.4M |
| Free cash flow | $37.2M | $15.4M | $17.9M | -$117.4M | -$39.6M |
| Diluted shares | 135.8M | 142.5M | 131.7M | 148.5M | 102.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $232.7M | $370.1M | $523.0M | $568.2M | $901.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $364.4M | $552.2M | $738.4M | $734.1M | $729.9M |
| Total assets | $499.8M | $685.7M | $929.1M | $1.00B | $1.22B |
| Total liabilities | $438.7M | $633.9M | $866.2M | $820.6M | $916.5M |
| Shareholders' equity | $61.1M | $51.8M | $62.9M | $182.5M | $302.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology